Bioorganic and medicinal chemistry letters (2020)
Update date:2022-08-04
Topics:
Dang Thi, Tuyet Anh
Le-Nhat-Thuy, Giang
Nguyen Hoang, Sa
Nguyen Thi, Huong
Nguyen Thi, Nga
Nguyen Thi, Thu Ha
Nguyen, Tuyen Van
Pham-The, Hai
A library of twelve quinazoline-triazole hybrid compounds were designed, synthesized and evaluated as a novel class of acetylcholinesterase inhibitors to treat Alzheimer's disease (AD). The biological assay results demonstrated the ability of several hybrid compounds to inhibit AChE enzyme (IC50 range = 0.2–83.9 μM). To understand the high potential activity of these compounds, molecular docking simulations were performed to get better insights into the mechanism of binding of quinazoline-triazole hybrid compounds. As expected, compounds 8a and 9a-b bind to both catalytic anionic site (CAS) and peripheral anionic site (PAS) in the active site of AChE enzyme, which implicates that these compounds could act as dual binding site inhibitors. These compounds were not cytotoxic and they also displayed appropriated physicochemical as well as pharmacokinetic profile to be developed as novel anti-AD drug candidates.
View Morepuyang hongda shengdao new material co.,ltd.
Contact:+86-393- 4896278
Address:No.29 East Zhongyuan Road
Liaoning Yufeng Chemical Co.,Ltd.
Contact:86-0419-3418888
Address:The metallurgical industrial zone,shoushan town, Liaoyang, Liaoning, China
Shanghai shibo Chemical Co., Ltd
Contact:+86-021-60753516
Address:688 Qiushi Road, Jinshan High-tech Park, Shanghai, China,201512
qingdao goldenchem imp and exp co.,ltd.
Contact:532-55579246
Address:no.62 ,haier road laoshan distirct
ChangZhou XiaQing Chemical Co., Ltd.
Contact:+86-519-88721665
Address:3# Hengluo Road, Henglin Town, Changzhou City, Jiangsu Province,China
Doi:10.1016/j.tetlet.2014.04.080
(2014)Doi:10.1039/c4ob00156g
(2014)Doi:10.1039/c4ob00356j
(2014)Doi:10.1021/acs.joc.6b00137
(2016)Doi:10.1039/c4cc01345j
(2014)Doi:10.1039/c4cc02279c
(2014)